Convergent Genomics Home
  • About Us
  • Our Products
  • Our Science
  • Clinical Expertise
  • Newsroom
  • Contact
  • About Us
  • Our Products
  • Our Science
  • Clinical Expertise
  • Newsroom
  • Contact

New Studies on Convergent Genomics’ Urine Test for Bladder Cancer to be Presented at 2023 American Urological Association (AUA) Annual Meeting

by admin | Apr 25, 2023 | Press releases

CHICAGO, April 25, 2023 /PRNewswire/ — Convergent Genomics announced UroAmp, the company’s genomic urine test that uses next-generation DNA sequencing and machine learning to detect and monitor for bladder cancer, will be the subject of two new studies...
Next Entries »

Contact us
425 Eccles Ave, South San Francisco, CA 94080
info@convergentgenomics.com
415-839-0077




Privacy Policy

Financial Conflict of
Interest Policy

References

CA: CDF-90003755     |      CLIA # 05D2220749     |      CAP Accredited # 9512563

The UroAmp test has been developed, its performance characteristics determined, and validated by our CLIA-certified and CAP-accredited laboratory, which performs the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.